glp 1 agonists with cardiovascular benefit agonist risks GLP-1 receptor agonist-based therapies and risk: a review of GLP-1 Agonists in Cardiovascular Diseases:

But a pill is still a powerful medicine

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 736 amide on gastric acid secretion in humans depends on an intact vagal innervation

Farxiga side effects Because Farxiga primarily removes glucose through the urine, it can lead to urinary tract infections (approximately 9% of Farxiga users) and genital yeast infections due to increased sugar in the urinary tract

The Genentech / Roche Group-backed drug GAZYVA (obinutuzumab) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with active Lupus Nephritis (LN) who are on standard therapy

D.et al (2010)